Active Rheumatoid Arthritis (RA) Clinical Trial (F2309) NURTURE study (CLOSED) September 2012 - 2014
A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety,
tolerability and long term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF agents.
1) Presence of RA as classified by ACR 2010 revised criteria for at least 3 months before screening.
2) Disease activity criteria defined by > or = 6 tender joints out of 68.
3) Patients must have been taking at least 1 anti-TNF agent such as etanercept, adalimumab, infliximab, certolizumab, or golimumab given at an approved
dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one
administration of an anti-TNF agent.
4) Patients must be taking MTX or any other DMARD (but not more than 1 DMARD) for at least 3 months before randomization and have to be on a stable
dose at least 4 weeks before randomization (7.5 to 25mg/week for MTX or maximum tolerated dose for other DMARD.
For more information, pleaase call 925-413-1451 Tim Davis, Research Coordinator
|Interested in Clinical Trials?
|Spondyloarthritis (SpA) /Back Pain Study June 2012 - August 2013 [COMPLETED]
A Multi-center Study of the Prevalance of Axial Spondyloarthritis (SpA) in the United States among Subjects with Chronic Back Pain and Other SpA-
Related Features. We are looking for adult patients who have NOT been previously diagnosed with any type of spondyloarthritis (ankylosing spondylitis, psoriatic arthritis, etc.)
who you have identified as having the following based on standard of care assessments in your practice:
1. chronic back pain for ≥ 3 months with age of onset < 45 years and
2. at least one of the following features:
Improvement with exercise
No improvement with rest
Pain at night with improvement upon getting up
c. Positive HLA-B27
The study will consist of only one study visit during which the patient will undergo:
- be asked to fill out patient reported health questionnaires, - have blood drawn for HLA-B27 (if not already done) and high sensitivity CRP,
- and be sent for an x-Ray and possible MRI (if not already done)
If you think you meet the above required parameters, please call: Victor RN at 510-791-1300 between 2pm and 5pm
|under control, you may be interested in this clinical study.
The REGAIN study is a clinical study for people with Rheumatoid Arthritis (CLOSED as of Oct 2014) The study
medication is approved for use in combination with methotrexate for RA. The purpose of this study is to assess the effects (good and bad) of the
investigational drug for RA in patients currently taking infliximab (Remicade® infusion) who still have symptoms of RA.
The study uses an open label design that moves subjects
from infliximab to the investigational drug.
Approximately 200 men and women will participate globally.
You may be able to participate if you:
• Have been diagnosed with RA AND
• While taking infliximab (Remicade® infusion) and methotrexate your response to infliximab (Remicade® infusion) is not as good as it once was,
even with its continued use.
If you are interested in learning more about how you may be eligible to participate in the REGAIN study or have any questions, please contact us at the
number below. Contacting us does not mean you have to participate or that you will be able to participate in the REGAIN Study. With your permission, and if
appropriate, we will schedule a screening visit at our study site to see if you are able to participate. Thank you for your consideration.
For more info, please call Victor Mo, RN 510-791-1300 between 2pm-5pm, mention REGAIN STUDY.
CNTO148-ART3003-ENG03 Version 1.0 11JUL2013, Approved by Sterling IRB: IRB ID: 4447C
|Rheumatoid Arthritis (RA). CNTO136ARA3005.
From 11/20/2014 -- 3/2015 - CLOSED
You may be able to participate if:
• You are 18 years or older
• You have been diagnosed with RA
• You have active symptoms
• You have NOT been treated with any Biologic drugs so far
• Treatment with methotrexate (MTX) has not helped you enough or is not appropriate for you
Other study requirements will also need to be met for you to be able to participate in the
SIRROUND-H Study. These requirements will be reviewed by the study doctor.
If you are able to participate in the SIRROUND-H Study, you will receive the investigational
medication, study-related physical examinations and study-related medical care at no charge.
Why should I take part in the SIRROUND-H Study?
There are many treatments for RA, including non-biologic drugs such as methotrexate.
However, not everyone will benefit from this treatment, and may continue to have active RA symptoms.
The SIRROUND-H Study will compare the effects of two different doses of investigational
medication with a marketed biologic drug in people for whom treatment with methotrexate (MTX) has not
helped enough or is not appropriate.
• Study participation will last about 1.5 years, with visits to
assigned to one of the three treatment groups.
• You will receive study treatment with either 2 different
doses of the investigational medication or with a marketed
biologic drug for about 52 weeks.
• At the end of the treatment, you will need to return to the
clinic for 4 more visits over 16 weeks.
• There will be some restrictions and prohibitions with regard
to other treatments for RA while you will be on study treatment.
If you or someone you know is interested in learning more about
the SIRROUND-H Study, please contact: Richelle, Study
Coordinator at 510-791-1300, and mention SIRROUND-H study.
|Previous Clinical Trials - Closed / Completed
|We are looking for volunteers for a study using an investigational device. (Flyer)
START: December 1st, 2015 - Feb 2016
Participants will be asked to spend approximately 30-45 minutes for the collection of vital signs, focusing on blood pressure. Participants will also have
their height and weight measured.
In order to participate in this study, you must:
• Be age 18 and over
• Be able to use your LEFT Hand to hold the device to your forehead
• NOT have any condition that prevents the staff from collecting blood pressure in the left or right arm
Why Participate? Participants will be introduced to a new noninvasive device in development, the Scanadu Scout™, to measure vital signs, including blood
pressure. Subjects will be compensated with a $25 gift card.
FOR MORE INFORMATION, PLEASE CONTACT: Fremont Rheumatology Office: 510-791-1300 - Call to schedule
3775 Beacon Ave, Ste 100, Fremont, CA 94538 Study Available Time: Afternoons between 1PM – 4:30PM (TUE, WED, FRI) Note: 1 time Visit only
Arthritis, Osteoporosis, and Auto-Immune Diseases
Barry Shibuya M.D. and Christine Elias M.D.